Facebook
Twitter
Telegram
Report an ErrorReata Pharmaceuticals Balance Sheet 2011-2024 | RETA
Annual Balance Sheet Reata Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
77.2 M | -454 M | - | -509 M | -259 M | -110 M | -84.7 M | -42 M | -87.8 M | -177 M | - | - |
Long Term Debt |
117 M | 133 M | - | 155 M | 79.2 M | 18.4 M | - | - | - | - | - | - |
Long Term Debt Current |
2.15 M | 3.14 M | 2.84 M | 3.16 M | - | 1.23 M | - | - | - | - | - | - |
Total Non Current Liabilities |
521 M | 495 M | 321 M | 234 M | 274 M | 235 M | 245 M | 291 M | 342 M | 391 M | - | - |
Total Current Liabilities |
59 M | 54 M | 119 M | 192 M | 55.9 M | 47.6 M | 59.6 M | - | - | - | - | - |
Total Liabilities |
- | - | - | 426 M | 330 M | 282 M | 304 M | 352 M | 400 M | 507 M | - | - |
Deferred Revenue |
- | 1.65 M | 4.69 M | 4.7 M | 31.3 M | 28.2 M | 46.6 M | 49.7 M | 49.6 M | 51 M | - | - |
Retained Earnings |
-1.57 B | -1.26 B | -958 M | -710 M | -420 M | -337 M | -289 M | -283 M | -282 M | -282 M | - | - |
Total Assets |
514 M | 735 M | 858 M | 682 M | 345 M | 135 M | 89.1 M | 79 M | 126 M | 229 M | - | - |
Cash and Cash Equivalents |
42.3 M | 590 M | 818 M | 664 M | 338 M | 130 M | 84.7 M | 42 M | 87.8 M | - | - | - |
Book Value |
514 M | 735 M | 858 M | 257 M | 15.2 M | -147 M | -215 M | -273 M | -274 M | -277 M | - | - |
Total Shareholders Equity |
-65.7 M | 186 M | 417 M | 257 M | 15.2 M | -147 M | -215 M | -273 M | -274 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Reata Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
115 M | 117 M | 135 M | 134 M | 136 M | 133 M | 57 K | 962 K | 1.73 M | - | - | - | 156 M | 155 M | 155 M | 155 M | 155 M | 79.2 M | 79.2 M | 78.6 M | 79.2 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
530 M | 521 M | 528 M | 517 M | 508 M | 495 M | 355 M | 343 M | 331 M | 321 M | 321 M | 321 M | 321 M | 234 M | 234 M | 234 M | 234 M | 274 M | 274 M | 274 M | 274 M | 235 M | 235 M | 235 M | 235 M | 245 M | 245 M | 245 M | 245 M | 291 M | 291 M | 291 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 755 K | 1.65 M | 2.56 M | 3.09 M | 3.89 M | 4.69 M | 4.69 M | 4.69 M | 4.69 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 31.3 M | 31.3 M | 31.3 M | 28.8 M | 28.2 M | 30.6 M | 36 M | 41.3 M | 46.6 M | 46.6 M | 46.6 M | 46.6 M | 49.7 M | 49.7 M | 49.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.68 B | -1.57 B | -1.48 B | -1.4 B | -1.33 B | -1.26 B | -1.17 B | -1.1 B | -1.03 B | -958 M | -958 M | -958 M | -958 M | -710 M | -710 M | -710 M | -710 M | -420 M | -420 M | -420 M | -420 M | -337 M | -337 M | -337 M | -337 M | -289 M | -289 M | -289 M | -289 M | -283 M | -283 M | -283 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
454 M | 514 M | 584 M | 632 M | 680 M | 735 M | 732 M | 778 M | 815 M | 858 M | 858 M | 858 M | 858 M | 682 M | 682 M | 682 M | 682 M | 345 M | 345 M | 345 M | 345 M | 135 M | 135 M | 135 M | 135 M | 89.1 M | 89.1 M | 89.1 M | 89.1 M | 79 M | 79 M | 79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
84.9 M | 42.3 M | 31.9 M | 147 M | 532 M | 590 M | 713 M | 756 M | 778 M | 818 M | 818 M | 818 M | 818 M | 664 M | 664 M | 664 M | 664 M | 338 M | 338 M | 338 M | 338 M | 130 M | 130 M | 130 M | 130 M | 84.7 M | 84.7 M | 84.7 M | 84.7 M | 42 M | 42 M | 42 M | - | 87.8 M | - | - | - | 177 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
454 M | 514 M | 584 M | 632 M | 680 M | 735 M | 732 M | 778 M | 815 M | 858 M | 858 M | 858 M | 858 M | 682 M | 682 M | 682 M | 682 M | 345 M | 345 M | 345 M | 345 M | 135 M | 135 M | 135 M | 135 M | 89.1 M | 89.1 M | 89.1 M | 89.1 M | 79 M | 79 M | 79 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-131 M | -65.7 M | 4.52 M | 68.6 M | 128 M | 186 M | 256 M | 314 M | 369 M | 417 M | 417 M | 417 M | 417 M | 257 M | 257 M | 257 M | 257 M | 15.2 M | 15.2 M | 15.2 M | 15.2 M | -147 M | -147 M | -147 M | -147 M | -215 M | -215 M | -215 M | -215 M | -273 M | -273 M | -273 M | - | -274 M | - | - | - | -277 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency